Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM5C | P41229 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.56 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375198 | 0.86 | MGAM (0.55) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL3267506 | 0.86 | PHF8 (0.62) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL7694256 | 0.85 | GAA (0.68) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL6111969 | 0.81 | KDM6B (0.80) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL27458892 | 0.79 | — | — | |
| SCHEMBL626477 | 0.79 | — | — | |
| SCHEMBL7096750 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL519939 | 0.77 | — | — | |
| SCHEMBL1427252 | 0.77 | KDM6B (0.65) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL1149136 | 0.75 | KDM6B (0.41) | KDM6BKDM5CEGLN1PHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109475574-A | Crosslinkable coating compositions formulated with dormant carbamate initiators | 海名斯精细化工公司 | 2019-03-15 | — | — | CN | disclosed |
| US-9732168-B2 | Method of preparing ethylene polymers by controlled high pressure polymerization | BASF SE (DE) | 2017-08-15 | — | — | US | disclosed |
| CN-103537822-A | High-concentration scaling powder for pre-forming soldering lug spraying | GUANGZHOU SOLDERWELL ADVANCED MATERIALS CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-20130150542-A1 | Method Of Preparing Ethylene Polymers By Controlled High Pressure Polymerization | BASF SE (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20110190412-A1 | PHOTOLATENT AMIDINE BASES FOR REDOX CURING OF RADICALLY CURABLE FORMULATIONS | BASF SE (US) | 2011-08-04 | — | — | US | disclosed |
| US-7820248-B2 | Coating composition comprising hydroxylamine esters | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7781471-B2 | Diaryl triazolmethylamine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20100210800-A1 | METHOD OF PREPARING ETHYLENE POLYMERS BY CONTROLLED HIGH PRESSURE POLYMERIZATION | CIBA CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1966167-B1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-06-16 | — | — | EP | disclosed |
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080234453-A1 | Method of Preparing Ethylene Polymers by Controlled High Pressure Polymerization | ROTH MICHAEL | 2008-09-25 | — | — | US | disclosed |
| EP-1966167-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | sanofi-aventis (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-7358311-B2 | Crosslinking of unsaturated polymers by the use of hydroxylamine-esters | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2007068814-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | WO | disclosed |
| US-7230042-B2 | Flame retardant polymer compositions containing hydroxylamine esters | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-06-12 | — | — | US | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | LTB4R2, LTB4R, CYSLTR1 | KDM6B 1208/4885KDM5C 1179/4885EGLN1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.